These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7742543)

  • 1. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells.
    Uckun FM; Stewart CF; Reaman G; Chelstrom LM; Jin J; Chandan-Langlie M; Waddick KG; White J; Evans WE
    Blood; 1995 May; 85(10):2817-28. PubMed ID: 7742543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
    Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
    Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
    Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
    Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
    Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
    Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
    Burris HA; Hanauske AR; Johnson RK; Marshall MH; Kuhn JG; Hilsenbeck SG; Von Hoff DD
    J Natl Cancer Inst; 1992 Dec; 84(23):1816-20. PubMed ID: 1331485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I.
    Kim JH; Kim SH; Kolozsvary A; Khil MS
    Int J Radiat Oncol Biol Phys; 1992; 22(3):515-8. PubMed ID: 1310495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
    Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
    Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios MB; Plunkett W; Keating MJ
    Blood; 1993 Mar; 81(5):1146-51. PubMed ID: 8382970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells.
    Myers DE; Jun X; Waddick KG; Forsyth C; Chelstrom LM; Gunther RL; Tumer NE; Bolen J; Uckun FM
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9575-9. PubMed ID: 7568175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of topotecan in malignant melanoma.
    Kraut EH; Walker MJ; Staubus A; Gochnour D; Balcerzak SP
    Cancer Invest; 1997; 15(4):318-20. PubMed ID: 9246152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
    Mattern MR; Hofmann GA; McCabe FL; Johnson RK
    Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
    Vey N; Giles FJ; Kantarjian H; Smith TL; Beran M; Jeha S
    Clin Cancer Res; 2000 Feb; 6(2):731-6. PubMed ID: 10690560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
    Uckun FM; Yang Z; Sather H; Steinherz P; Nachman J; Bostrom B; Crotty L; Sarquis M; Ek O; Zeren T; Tubergen D; Reaman G; Gaynon P
    Blood; 1997 May; 89(10):3769-77. PubMed ID: 9160683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
    Teicher BA; Holden SA; Khandakar V; Herman TS
    J Cancer Res Clin Oncol; 1993; 119(11):645-51. PubMed ID: 8394365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
    Vassal G; Pondarré C; Cappelli C; Terrier-Lacombe MJ; Boland I; Morizet J; Bénard J; Vénuat AM; Ardouin P; Hartmann O; Gouyette A
    Eur J Cancer; 1997 Oct; 33(12):2011-5. PubMed ID: 9516844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Beran M; Kantarjian H; O'Brien S; Koller C; al-Bitar M; Arbuck S; Pierce S; Moore M; Abbruzzese JL; Andreeff M; Keating M; Estey E
    Blood; 1996 Oct; 88(7):2473-9. PubMed ID: 8839838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase I inhibitors: topotecan and irenotecan.
    Creemers GJ; Lund B; Verweij J
    Cancer Treat Rev; 1994 Jan; 20(1):73-96. PubMed ID: 8293429
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.